Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | ASP5878 |
| Synonyms | |
| Therapy Description |
ASP5878 is an inhibitor of FGFR1-4 that inhibits tumor cell proliferation (Mol Cancer Ther December 2015 14; A170, PMID: 31167419). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| ASP5878 | FGFR Inhibitor (Pan) 26 | ASP5878 is an inhibitor of FGFR1-4 that inhibits tumor cell proliferation (Mol Cancer Ther December 2015 14; A170, PMID: 31167419). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| FGFR3 S249C | urinary bladder cancer | sensitive | ASP5878 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, ASP5878 treatment inhibited proliferation of a bladder cancer cell line harboring FGFR3 S249C in culture, and resulted in tumor regression in xenograft models (Mol Cancer Ther December 2015 14; A170). | detail... |
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT02038673 | Phase I | ASP5878 | An Open-label Phase I Study of Oral ASP5878 at Single and Multiple Doses in Patients With Solid Tumors | Completed | USA | 3 |